MX2011011615A - Uso de acidos grasos poliinsaturados (pufas) para tratar daño del nervio. - Google Patents

Uso de acidos grasos poliinsaturados (pufas) para tratar daño del nervio.

Info

Publication number
MX2011011615A
MX2011011615A MX2011011615A MX2011011615A MX2011011615A MX 2011011615 A MX2011011615 A MX 2011011615A MX 2011011615 A MX2011011615 A MX 2011011615A MX 2011011615 A MX2011011615 A MX 2011011615A MX 2011011615 A MX2011011615 A MX 2011011615A
Authority
MX
Mexico
Prior art keywords
cis
group
alkyl
different
same
Prior art date
Application number
MX2011011615A
Other languages
English (en)
Spanish (es)
Inventor
Adam Kelliher
Norman Cameron
Angus Morrison
Phil Knowles
Original Assignee
Equateq Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equateq Ltd filed Critical Equateq Ltd
Publication of MX2011011615A publication Critical patent/MX2011011615A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2011011615A 2009-05-01 2010-04-22 Uso de acidos grasos poliinsaturados (pufas) para tratar daño del nervio. MX2011011615A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0907601.9A GB0907601D0 (en) 2009-05-01 2009-05-01 Novel methods
PCT/GB2010/000817 WO2010125330A1 (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage

Publications (1)

Publication Number Publication Date
MX2011011615A true MX2011011615A (es) 2012-01-27

Family

ID=40792178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011615A MX2011011615A (es) 2009-05-01 2010-04-22 Uso de acidos grasos poliinsaturados (pufas) para tratar daño del nervio.

Country Status (14)

Country Link
US (1) US20120122982A1 (cg-RX-API-DMAC10.html)
EP (1) EP2424519A1 (cg-RX-API-DMAC10.html)
JP (1) JP5608220B2 (cg-RX-API-DMAC10.html)
KR (1) KR101664518B1 (cg-RX-API-DMAC10.html)
CN (1) CN102448453B (cg-RX-API-DMAC10.html)
AU (1) AU2010243368C1 (cg-RX-API-DMAC10.html)
BR (1) BRPI1009922A2 (cg-RX-API-DMAC10.html)
CA (1) CA2762009C (cg-RX-API-DMAC10.html)
GB (1) GB0907601D0 (cg-RX-API-DMAC10.html)
MX (1) MX2011011615A (cg-RX-API-DMAC10.html)
NZ (1) NZ596674A (cg-RX-API-DMAC10.html)
SG (1) SG175848A1 (cg-RX-API-DMAC10.html)
WO (1) WO2010125330A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201108571B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
ES2727387T3 (es) * 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3261684D1 (en) * 1981-05-12 1985-02-07 Ici Plc Pyrrole derivatives
US4532254A (en) * 1983-03-17 1985-07-30 Kaken Pharmaceutical Co., Ltd. Inhibitor of aldose reductase
AU599515B2 (en) * 1987-09-16 1990-07-19 Taiho Pharmaceutical Co., Ltd. Thienopyrimidine derivatives
EP2140863A1 (en) * 1993-06-09 2010-01-06 Martek Biosciences Corporation Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of neurological disorders
US7015249B1 (en) * 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
US6107349A (en) * 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
GB9827391D0 (en) * 1998-12-11 1999-02-03 Fundation O N C F Aldose reductase inhibitors and pharmaceutical compositions
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
ES2240657T3 (es) * 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
AU2002304931A1 (en) * 2001-06-08 2002-12-23 University Of British Columbia Methods for treating disorders of the nervous and reproductive systems
ES2536710T3 (es) * 2002-03-25 2015-05-27 Arimed Inc. Nuevo uso terapéutico de LPC, ligandos agonistas específicos para el receptor G2A
WO2006137435A1 (ja) * 2005-06-22 2006-12-28 National University Corporation Gunma University Gタンパク質共役型受容体g2aの作動薬、及びg2a活性調節薬のスクリーニング方法
EP2179999A4 (en) * 2007-12-18 2011-06-08 Univ Toyama Nat Univ Corp CONDENSED TRICYCLIC COMPOUND WITH ALDOSIS REDUCTASE HARMFUL EFFECT

Also Published As

Publication number Publication date
CA2762009C (en) 2016-11-22
JP5608220B2 (ja) 2014-10-15
AU2010243368A1 (en) 2011-12-15
EP2424519A1 (en) 2012-03-07
AU2010243368C1 (en) 2014-04-03
GB0907601D0 (en) 2009-06-10
KR20120023729A (ko) 2012-03-13
SG175848A1 (en) 2011-12-29
AU2010243368B2 (en) 2013-10-24
CA2762009A1 (en) 2010-11-04
KR101664518B1 (ko) 2016-10-11
WO2010125330A1 (en) 2010-11-04
NZ596674A (en) 2013-09-27
JP2012525362A (ja) 2012-10-22
BRPI1009922A2 (pt) 2016-03-15
US20120122982A1 (en) 2012-05-17
CN102448453A (zh) 2012-05-09
CN102448453B (zh) 2016-07-06
ZA201108571B (en) 2013-01-30

Similar Documents

Publication Publication Date Title
CA2866067C (en) Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
Lee et al. Palmitic acid methyl ester is a novel neuroprotective agent against cardiac arrest
JP2010248230A (ja) スタチン副作用の処置
AU2018257483B2 (en) Topical pharmaceutical composition comprising at least amitriptyline, for the treatment of peripheral neuropathic pain
CN117377476B (zh) 治疗与化学疗法诱发的周围神经病变相关的疼痛
JP2016540771A (ja) セロトニン−ノルアドレナリン再取り込み阻害薬(snri)およびシグマ受容体リガンドの組み合わせ
AU2010243368C1 (en) Use of PUFAs to treat nerve damage
US5516801A (en) Fatty acid treatment for ectopic calcium deposition
KR20230142708A (ko) Pqq 및 이의 유도체의 신규한 응용
AU666748B2 (en) Fatty acid treatment
França-Silva et al. The new nitric oxide donor 2-nitrate-1, 3-dibuthoxypropan alters autonomic function in spontaneously hypertensive rats
BR112020011401A2 (pt) combinação de moduladores de receptor nmda (rapastinel) para uso em tratamento combinado (distúrbio do sono e do snc)
WO2022004788A1 (ja) 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤
US8975298B2 (en) Therapeutic agent for pain
Cho et al. Adenosine and cholinergic-induced gastric contraction in rats
EP4262777A1 (en) Treatment of amyotrophic lateral sclerosis using pkc activators
Burton et al. (301) Pharmacological activation of AMPK inhibits incision-evoked mechanical hypersensitivity and the transition to a chronic pain state
Qiu (302) Signaling events underlying the analgesic effect of propofol
Patil et al. (300) Prolactin regulates sensory neurons in a female-specific manner at their peripheral and central terminals and not at their cell bodies
Popoli et al. CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease
Salmasi et al. Influence of adenosine and ADP on expression of surface antigens of human T-lymphocytes is connected with stimulation of single type of purine receptors
Poli et al. Functional interactions between adenosine A1 and class II of metabotropic glutamate receptors in rat hippocampus
CA2880399A1 (en) Use of bimatoprost free acid administered to the skin to reduce adipose tissue
TW200524920A (en) Treatment of circadian rhythm disorders with NPY Y5 receptor antagonist

Legal Events

Date Code Title Description
FG Grant or registration